News Releases Year None20242023202220212020201920182017 NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference May 27, 2020 NuCana Reports First Quarter 2020 Financial Results and Provides Business Update May 19, 2020 NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic May 18, 2020 NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 May 15, 2020 NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) May 05, 2020 NuCana Provides Update on Impact of COVID-19 on Clinical Studies Apr 02, 2020 NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update Mar 10, 2020 NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Mar 10, 2020 NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020 NuCana to Present at the Cowen and Company 40th Annual Health Care Conference Feb 25, 2020 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic May 18, 2020
NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020 May 15, 2020
NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121) May 05, 2020
NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update Mar 10, 2020
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer Mar 10, 2020
NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer Mar 04, 2020